Loading stock data…
Glaukos Corporation (GKOS)
$153.58+1.45 (+0.95%)
Market ClosedLast close Jul 24
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Glaukos Corporation in the Healthcare sector is trading at $153.58 with a market capitalization of $6.7B. Wall Street consensus targets $165.00 (12 analysts), implying a +7.4% move over the next 12 months. The stock is currently near its 52-week high of $161.53, remaining 33.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $150.57M↑ | $143.12M↑ | $133.54M↑ | $124.12M↑ | $106.66M |
| Gross Profit | $117.23M↑ | -$1.52M↓ | $104.71M↑ | $97.22M↑ | $82.35M |
| Operating Income | -$19.86M↑ | -$139.87M↓ | -$16.36M↑ | -$22.69M↓ | -$20.68M |
| Net Income | -$19.78M↑ | -$133.66M↓ | -$16.23M↑ | -$19.66M↓ | -$18.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.22%
Volume
Today's trading volume
289,187
Recent News
Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
This Glaucoma Therapy Company Is Keeping An Eye On Profits
This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.